rhGM-CSF Helps Patients with Brain Cancer
Author Information
Author(s): R. Rampling, W. Steward, J. Paul, M.A. Macham, E. Harvey, D. Eckley
Primary Institution: Beatson Oncology Centre and CRC Clinical Trials Unit, Western Infirmary, Glasgow
Hypothesis
Can rhGM-CSF reduce the haematological toxicity of BCNU in patients with malignant glioma?
Conclusion
The study found that rhGM-CSF significantly increased the nadir neutrophil count in patients treated with BCNU.
Supporting Evidence
- 12 out of 13 patients had a higher nadir neutrophil count during rhGM-CSF cycles.
- The median nadir was significantly higher in cycles with rhGM-CSF.
- Five episodes of neutropenia occurred during unprotected cycles compared to none in rhGM-CSF cycles.
Takeaway
This study shows that a special medicine called rhGM-CSF can help people with brain cancer by making their blood counts better when they take another medicine.
Methodology
A prospective, randomised crossover study was conducted with patients receiving BCNU for relapsed glioblastoma, comparing cycles with and without rhGM-CSF.
Limitations
The study had a small sample size and some patients were excluded from the efficacy analysis due to disease progression.
Participant Demographics
The median age of participants was 46, with a mix of male and female patients, and most had recurrent malignant glioma.
Statistical Information
P-Value
0.005
Confidence Interval
0.76-3.52
Statistical Significance
p<0.005
Want to read the original?
Access the complete publication on the publisher's website